泽璟制药-U
(688266)
| 流通市值：283.77亿 | | | 总市值：283.77亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 375,650,273.55 | 167,641,962.39 | 532,954,371.3 | 384,117,191.62 |
| 营业收入 | 375,650,273.55 | 167,641,962.39 | 532,954,371.3 | 384,117,191.62 |
| 二、营业总成本 | 475,168,324.66 | 224,891,718.58 | 726,897,941.91 | 509,620,185.43 |
| 营业成本 | 38,820,914.93 | 19,467,832.72 | 36,991,445.8 | 27,024,454.43 |
| 税金及附加 | 3,926,379.78 | 752,388.88 | 1,448,782.82 | 867,445.09 |
| 销售费用 | 211,258,113.88 | 94,063,802.54 | 271,447,660.35 | 189,668,174.67 |
| 管理费用 | 38,686,242.34 | 15,073,925.75 | 58,187,706.06 | 41,035,357.09 |
| 研发费用 | 196,503,538.35 | 102,236,990.94 | 387,998,981.13 | 272,787,045.8 |
| 财务费用 | -14,026,864.62 | -6,703,222.25 | -29,176,634.25 | -21,762,291.65 |
| 其中:利息费用 | 13,872,494.79 | 7,205,839.97 | 28,892,922.3 | 21,794,742.26 |
| 其中:利息收入 | 28,160,739.61 | 14,056,559.81 | 58,287,813.71 | 43,673,487.35 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 3,919,137.25 | 3,902,701.58 |
| 加:投资收益 | 800,771.56 | 432,028.59 | 2,939,351.7 | 2,407,009.09 |
| 资产处置收益 | 810.44 | 3,080,043.7 | - | - |
| 资产减值损失(新) | -3,358,109.26 | - | - | - |
| 信用减值损失(新) | -1,738,783.39 | 279,528.06 | -3,758,982.85 | -3,158,148.94 |
| 其他收益 | 27,082,192.48 | 23,441,133.52 | 35,800,880.73 | 9,803,330.56 |
| 四、营业利润 | -76,731,169.28 | -30,017,022.32 | -155,043,183.78 | -112,548,101.52 |
| 加:营业外收入 | - | - | 3,681.42 | 3,681.42 |
| 减:营业外支出 | 683,818.74 | 300,000 | 8,304.43 | 58,304.43 |
| 五、利润总额 | -77,414,988.02 | -30,317,022.32 | -155,047,806.79 | -112,602,724.53 |
| 减:所得税费用 | -1,845,042.52 | -1,003,660.05 | -4,749,483.88 | -2,956,159.52 |
| 六、净利润 | -75,569,945.5 | -29,313,362.27 | -150,298,322.91 | -109,646,565.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -75,569,945.5 | -29,313,362.27 | -150,298,322.91 | -109,646,565.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -72,803,538.99 | -28,262,235.13 | -137,830,775.59 | -97,902,983.29 |
| 少数股东损益 | -2,766,406.51 | -1,051,127.14 | -12,467,547.32 | -11,743,581.72 |
| 扣除非经常损益后的净利润 | -102,641,422.42 | -50,080,962.78 | -171,160,269.29 | -104,556,818.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.28 | -0.11 | -0.52 | -0.37 |
| (二)稀释每股收益 | -0.28 | -0.11 | -0.52 | -0.37 |
| 八、其他综合收益 | -477,198.95 | 140,191.46 | -8,749,199.69 | 26,035,078.95 |
| 归属于母公司股东的其他综合收益 | -416,776.37 | 138,889.09 | -8,524,610.6 | 24,168,674.87 |
| 九、综合收益总额 | -76,047,144.45 | -29,173,170.81 | -159,047,522.6 | -83,611,486.06 |
| 归属于母公司股东的综合收益总额 | -73,220,315.36 | -28,123,346.04 | -146,355,386.19 | -73,734,308.42 |
| 归属于少数股东的综合收益总额 | -2,826,829.09 | -1,049,824.77 | -12,692,136.41 | -9,877,177.64 |
| 公告日期 | 2025-08-23 | 2025-04-19 | 2025-04-19 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |